FDA Reissues Warnings on Compounded Semaglutide Due to Safety Concerns

The FDA has again cautioned against compounded semaglutide, highlighting that these products bypass the rigorous pre-market approval process of brand-name drugs. This lack of oversight means their dosage accuracy, sterility, and long-term safety are unverified, posing significant quality and safety risks to consumers. While compounding may be permitted during shortages under "enforcement discretion," this does not imply FDA approval or endorsement of their safety.